Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$462.88 USD
-0.27 (-0.06%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $462.85 -0.03 (-0.01%) 7:28 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$462.88 USD
-0.27 (-0.06%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $462.85 -0.03 (-0.01%) 7:28 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Zacks News
Is a Beat in Store for Royalty Pharma (RPRX) in Q3 Earnings?
by Zacks Equity Research
Some of the drugs under Royalty Pharma's (RPRX) royalty acquisition agreements performed well during the third quarter while others declined or flatlined.
Biotech Stock Roundup: Gilead, Amgen, Vertex and Alexion Report Q3 Earnings & More
by Zacks Equity Research
Third-quarter earnings take centerstage in the biotech sector as Gilead (GILD), Amgen (AMGN) and others report results.
Moderna (MRNA) Q3 Earnings Lag Estimates, Pipeline Advances
by Zacks Equity Research
Moderna (MRNA) reports wider-than-expected third-quarter loss. However, revenues beat estimates significantly. Shares up presumably on encouraging pipeline progress and rising cash resources.
Vertex (VRTX) Beats on Q3 Earnings & Sales, Ups Sales View
by Zacks Equity Research
Vertex (VRTX) beats estimates for both earnings and sales and raises revenue guidance for 2020.
Vertex Pharmaceuticals (VRTX) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of 10.46% and 3.38%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Can Coronavirus Vaccine Efforts Aid Novavax (NVAX) Q3 Earnings?
by Zacks Equity Research
During Novavax's (NVAX) upcoming third-quarter earnings call, investor focus will be on the company's progress with its COVID-19 vaccine candidate NVX-CoV2373.
What's in Store for ADMA Biologics' (ADMA) Q3 Earnings?
by Zacks Equity Research
On ADMA Biologics' (ADMA) third-quarter earnings call, investor focus will be on the sales performance of its newly approved immunoglobulin products, Asceniv and Bivigam.
Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on any update on the timeline for filing for emergency use authorization of Modena's (MRNA) coronavirus vaccine candidate on the third-quarter earrings call.
Mattel, PLCE, Gilead, Vertex and Horizon as Zacks Bull and Bear of the Day
by Zacks Equity Research
Mattel, PLCE, Gilead, Vertex and Horizon as Zacks Bull and Bear of the Day
What's in the Cards for Cassava (SAVA) This Earnings Season?
by Zacks Equity Research
Investors will be keen on updates from the recent study on its lead candidate, sumifilam, when Cassava (SAVA) reports Q3 results.
Can Trikafta Drive Vertex's (VRTX) Revenues in Q3 Earnings?
by Zacks Equity Research
On Vertex's (VRTX) third-quarter earnings call, investor focus will be on the sales performance of its triple combo CF drug Trikafta and the probable impact of COVID-19 on the same.
Will Coronavirus Woes Affect Gilead's (GILD) Q3 Earnings?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and the uptake of Yescarta along with updates on experimental coronavirus treatment, when Gilead (GILD) reports third-quarter 2020 results.
CRISPR (CRSP) Falls Despite Positive Data on Lymphoma Study
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reports top-line data from a phase I study, currently evaluating its pipeline candidate CTX110 for CD19+ B-cell malignancies. Shares down.
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: BIIB Posts Q3 Results, VRTX Stops Study & Other Updates
by Zacks Equity Research
The biotech sector was in focus as Biogen's (BIIB) Q3 results disappoint, Vertex (VRTX) stops study and Regeneron's (REGN) Ebola drug gets FDA approval.
AstraZeneca's (AZN) Tagrisso sNDA Receives Priority Review
by Zacks Equity Research
AstraZeneca's (AZN) regulatory application for label expansion of Tagrisso to include adjuvant treatment of patients with early-stage EGFR-mutated lung cancer gets FDA's apriority review.
Zacks.com featured highlights include: Meritage Homes, Vertex Pharmaceuticals, CVS Health, Amedisys and Insperity
by Zacks Equity Research
Zacks.com featured highlights include: Meritage Homes, Vertex Pharmaceuticals, CVS Health, Amedisys and Insperity
Zacks.com featured highlights include: Vertex Pharmaceuticals, PerkinElmer, Stanley Black & Decker, 3M and Arthur J. Gallagher & Co
by Zacks Equity Research
Zacks.com featured highlights include: Vertex Pharmaceuticals, PerkinElmer, Stanley Black & Decker, 3M and Arthur J. Gallagher & Co
Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (VRTX) Outperforming Other Medical Stocks This Year?
AstraZeneca (AZN) Gets CHMP Nod for Forxiga in Heart Failure
by Zacks Equity Research
The CHMP passes a favorable opinion for the approval of AstraZeneca's (AZN) Forxiga for the treatment of symptomatic chronic HFrEF in adults with and without type-II diabetes.
Endo (ENDP) Gains on Deal to Acquire BioSpecifics for $540M
by Zacks Equity Research
Endo (ENDP) gains from the acquisition of commercial-stage biopharmaceutical company, BioSpecifics Technologies Corp.
Pick These 5 Stocks With Superb Interest Coverage Ratio
by Sumit Singh
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Companies such as Meritage Homes (MTH), Vertex Pharmaceuticals (VRTX), CVS Health (CVS), Amedisys (AMED) and Insperity (NSP) are sound enough to meet financial obligations.
Bet on These 5 Top-Ranked Stocks With Strong Sales Growth
by Swayta Shah
Robust sales growth is an important characteristic of potential stock market winners. Let's check out - Vertex Pharmaceuticals (VRTX), PerkinElmer (PKI), Stanley Black & Decker (SWK), 3M Company (MMM) and Arthur J. Gallagher (AJG) - as these are likely to see solid sales growth.
Vertex Pharmaceuticals (VRTX) Enters Oversold Territory
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $220.51 in the latest trading session, marking a +1.11% move from the prior day.